Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

Aims/hypothesesChronic hyperglycaemia increases dipeptidyl peptidase IV (DPP-IV) activity in endothelial cells in vitro. The present study was designed to assess the effect of high glucose on circulating DPP-IV activity in patients with type 1 and type 2 diabetes.MethodsPlasma DPP-IV activity was measured in 29 patients with type 1 diabetes and 29 age-, sex- and BMI-matched control subjects. We also assessed DPP-IV activity in 31 type 2 diabetic patients with HbA1c >8.5% and in plasma from matched groups of 31 newly diagnosed diabetic subjects with HbA1c <7.5%, 31 subjects with IGT and 62 subjects with NGT. In a further sample of 66 type 2 diabetic patients, a longitudinal study was also performed to evaluate variations in DPP-IV activity and HbA1c over 3 months.ResultsDPP-IV activity in type 1 diabetic patients was not significantly different from that in control subjects; however, a significant correlation between DPP-IV and HbA1c was observed in diabetic subjects (r=0.47; p<0.01). Type 2 diabetic patients with HbA1c >8.5% showed significantly (p<0.05) higher DPP-IV activity (mean±SD 27.7±7.1 U/l) than newly diagnosed diabetic patients and subjects with IGT (22.1±6.0 and 18.8±8.8 U/l, respectively). Variations in DPP-IV activity over 3 months in type 2 diabetic patients showed a significant positive correlation with variations in HbA1c (r=0.26; p<0.05).Conclusions/interpretationChronic hyperglycaemia induces a significant increase in DPP-IV activity in type 1 and type 2 diabetes. This phenomenon could contribute to the reduction in circulating active glucagon-like peptide-1 and to the consequent postprandial hyperglycaemia in type 2 diabetic patients with poor metabolic control.

[1]  M. Iotti,et al.  Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes. , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[2]  C. Bailey,et al.  Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39). , 2004, Metabolism: clinical and experimental.

[3]  J. Holst,et al.  Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.

[4]  J. Holst,et al.  Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[5]  J. Holst,et al.  The Inhibitory Effect of Glucagon-Like Peptide-1 (7-36)amide on Antral Motility is Antagonized by Its N-Terminally Truncated Primary Metabolite GLP-1 (9-36)amide , 1998, Peptides.

[6]  S. Kahn,et al.  Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. , 1994, The Journal of clinical investigation.

[7]  H. Neels,et al.  Reference Values for Plasma Dipeptidyl Peptidase IV Activity and Their Association with Other Laboratory Parameters , 2001, Clinical chemistry and laboratory medicine.

[8]  E. Mannucci,et al.  Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. , 2003, Biochemical and biophysical research communications.

[9]  J. Holst,et al.  Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. , 1996, European journal of endocrinology.

[10]  D Conen,et al.  Glucagon-like peptide-1: a potent regulator of food intake in humans , 1999, Gut.

[11]  S. Bloom,et al.  Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. , 1999, Diabetes.

[12]  B. Gallwitz,et al.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.

[13]  J. Holst,et al.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.

[14]  B. Göke,et al.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. , 1998, The Journal of clinical investigation.

[15]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[16]  C. Durinx,et al.  The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors. , 1999, Current medicinal chemistry.

[17]  E. Mannucci,et al.  Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance , 2003, Acta Diabetologica.

[18]  R. Pederson,et al.  Effect of ageing and diabetes on glucose‐dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[19]  J. Kozarich,et al.  Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. , 2003, Current opinion in chemical biology.

[20]  E. Mannucci,et al.  Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. , 2001, Diabetes care.

[21]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[22]  B. Göke,et al.  Incretin hormone expression in the gut of diabetic mice and rats. , 1997, Metabolism: clinical and experimental.

[23]  E. Mannucci,et al.  Glucagon‐like peptide (GLP)‐1 and leptin concentrations in obese patients with Type 2 diabetes mellitus , 2000, Diabetic medicine : a journal of the British Diabetic Association.